AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

NEXT STORY
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
PREV STORY
The industrial & institutional disinfectants & sanitizers market by revenue is expected to grow at a CAGR of 10.21% during the period 2020–2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

author_avatar
NASDAQ Market News

Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers

SANTA MONICA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today ...

author_avatar
NASDAQ Market News

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

author_avatar
NASDAQ Market News